SCHEMBL1380180

SCHEMBL1380180

Cc1cc(C(=O)Nc2cccc(OCc3c(F)ccc(Cl)c3F)c2)c(C)n1-c1ccccc1C(F)(F)F

nearest known ligand 0.46

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ NOTUM Q6P988 2/20 0.41
▸ KCNK3 O14649 1/20 0.41
▸ KCNK9 Q9NPC2 1/20 0.41
▸ RXFP1 Q9HBX9 2/20 0.40
▸ POLB P06746 1/20 0.40
▸ MAPT P10636 2/20 0.40
▸ MAPK1 P28482 1/20 0.40
▸ NPSR1 Q6W5P4 1/20 0.40
▸ NR3C2 P08235 2/20 0.39
▸ TRPV4 Q9HBA0 1/20 0.39
▸ LMNA P02545 3/20 0.39
▸ TP53 P04637 2/20 0.39
▸ TAAR1 Q96RJ0 1/20 0.39
▸ SGMS2 Q8NHU3 1/20 0.38
▸ RAB9A P51151 2/20 0.38
▸ GAA P10253 1/20 0.38
▸ NPC1 O15118 1/20 0.38
▸ AKR1C3 P42330 1/20 0.37
▸ LRRK2 Q5S007 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2025687 0.94 KCNK3 (0.46) NOTUMKCNK3KCNK9RXFP1POLB
SCHEMBL1378988 0.93 KCNK3 (0.43) KCNK3KCNK9RXFP1POLBMAPT
SCHEMBL1385281 0.92 SGMS2 (0.46) NOTUMKCNK3KCNK9RXFP1POLB
SCHEMBL1383435 0.91 KCNK3 (0.46) NOTUMKCNK3KCNK9RXFP1POLB
SCHEMBL1381619 0.90 POLB (0.45) NOTUMKCNK3KCNK9RXFP1POLB
SCHEMBL1380273 0.90 KCNK3 (0.45) NOTUMKCNK3KCNK9RXFP1POLB
SCHEMBL1384431 0.89 SGMS2 (0.46) NOTUMKCNK3KCNK9RXFP1POLB
SCHEMBL2027825 0.88 KCNK3 (0.44) KCNK3KCNK9RXFP1POLBMAPT
SCHEMBL1382399 0.87 SGMS2 (0.45) KCNK3KCNK9RXFP1MAPTMAPK1
SCHEMBL1382369 0.87 SGMS2 (0.46) NOTUMKCNK3KCNK9RXFP1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-4703649-B2 — — 2011-06-15 — — JP claimed
US-8026237-B2 For modulating activity of one or more steroid nuclear receptors and for treatment, prevention, or amelioration of symptoms of disease or disorder related to the activity of receptors; 5-benzo[b]thiophen-2-yl-1,4-dimethyl-1H-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl)-amide EXELIXIS, INC. (US) 2011-09-27 — — US disclosed
US-8026237-B2 For modulating activity of one or more steroid nuclear receptors and for treatment, prevention, or amelioration of symptoms of disease or disorder related to the activity of receptors; 5-benzo[b]thiophen-2-yl-1,4-dimethyl-1H-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl)-amide EXELIXIS, INC. (US) 2011-09-27 — — US disclosed
US-8026237-B2 For modulating activity of one or more steroid nuclear receptors and for treatment, prevention, or amelioration of symptoms of disease or disorder related to the activity of receptors; 5-benzo[b]thiophen-2-yl-1,4-dimethyl-1H-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl)-amide EXELIXIS, INC. (US) 2011-09-27 — — US disclosed
US-20080234270-A1 Pyrrole Derivatives As Pharmaceutical Agents EXELIXIS, INC. (US) 2008-09-25 — — US disclosed
US-20080234270-A1 Pyrrole Derivatives As Pharmaceutical Agents EXELIXIS, INC. (US) 2008-09-25 — — US disclosed
US-20080234270-A1 Pyrrole Derivatives As Pharmaceutical Agents EXELIXIS, INC. (US) 2008-09-25 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080234270-A1 Pyrrole Derivatives As Pharmaceutical Agents PRLHR, PTGDR, TACR1 NOTUM 1646/4885KCNK3 3073/4885KCNK9 3876/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback